leisure time -WSS

leisure time

author：explore 2025-09-27 19:28:56 - browse：275

BiTE Bridge — Illustration of a BiTE, Amgen's bispecific antibodies Amgen

In cancer immunotherapy these days, technology is advancing so fast that 2017’s buzzy new treatment may soon be passe: Only 18 months after approval of the first CAR-T, pharmaceutical companies and biotechs are already talking about next-generation cancer therapy.

Called bispecific antibodies, they’re being developed by some two dozen companies large and small, with a version cleverly branded as BiTEs already constituting 60 percent of Amgen’s oncology pipeline. The appeal: Bispecifics make the immune system kill tumor cells like first-gen immunotherapy, but, unlike the weeks it takes to laboriously manufacture CAR-Ts, they can start being infused almost as quickly as an oncologist can write a prescription.

“We’re very bullish” on BiTEs, said Dr. David Reese, head of R&D at Amgen, which has the only cancer-targeting bispecific approved for clinical use in the U.S. and 14 more in development, including for multiple myeloma, small cell lung cancer, glioblastoma, and other solid tumors. “We can generate a BiTE against any tumor antigen we want to go after.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Copay coupons to count toward deductibles, after Biden court move

WSS

$1 billion proposal to grow Boston, Massachusetts biotech

Streamlined flu vaccines recommended by FDA advisory panel

Francis Collins on trust in science and how Covid communications failed

Streamlined flu vaccines recommended by FDA advisory panel

Dewpoint Therapeutics lays off staff after losing partnerships

Why Talkspace is targeting Medicare, a tricky market

Wikipedia

leisure time

focus

Duchenne breakthrough therapy leaves behind pioneering families

$1 billion proposal to grow Boston, Massachusetts biotech

Hollywood unions extend contract negotiations for actors

Medicare drug price negotiation hearing pits pharma v Biden admin

Trump demands the U.S. pay no more for drugs than other countries … again

First over

DIEP, the 'gold standard' of breast reconstruction, is under threat

Parkinson’s finding may lead to tests and, someday, treatments

DIEP, the 'gold standard' of breast reconstruction, is under threat

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

Wikipedia

Stem cell biologist probes earliest stages of human development

Ancient Greek ideas underpin modern concepts of pregnancy

Ozempic has benefits for kidney disease as well as diabetes

The surgeon had a dilemma only a Nazi medical text could resolve

Parkinson’s finding may lead to tests and, someday, treatments

A new approach to psychiatric drug development

focus

hotspot

entertainment

focus